| 14.7 -0.12 (-0.81%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.61 | 1-year : | 20.57 |
| Resists | First : | 15.07 | Second : | 17.61 |
| Pivot price | 14.89 |
|||
| Supports | First : | 14.26  |
Second : | 13.76 |
| MAs | MA(5) : | 14.82 |
MA(20) : | 14.86 |
| MA(100) : | 13.64 |
MA(250) : | 14.08 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 25.3 |
D(3) : | 36.9 |
| RSI | RSI(14): 53.7 |
|||
| 52-week | High : | 16.38 | Low : | 12.57 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TAK ] has closed below the lower bollinger band by 4.7%. Bollinger Bands are 56.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.87 - 14.95 | 14.95 - 15.01 |
| Low: | 14.49 - 14.57 | 14.57 - 14.63 |
| Close: | 14.58 - 14.71 | 14.71 - 14.81 |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Tue, 10 Sep 2024
530,600 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Cowen AND Company LLC - MarketBeat
Sun, 08 Sep 2024
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production - MSN
Wed, 28 Aug 2024
Takeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers - Yahoo Finance
Wed, 26 Jun 2024
Takeda Announces New Assignments of Directors - StockTitan
Tue, 11 Jun 2024
Takeda Pharmaceutical Unveils Employee Incentive Plan - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 510,870 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.17e+009 (%) |
| Held by Institutions | 1.55e+009 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.9 |
| Profit Margin | 580 % |
| Operating Margin | 3.4 % |
| Return on Assets (ttm) | 15.9 % |
| Return on Equity (ttm) | 2 % |
| Qtrly Rev. Growth | 4.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 12.56 |
| PEG Ratio | 230 |
| Price to Book value | 3 |
| Price to Sales | 3.68127e+012 |
| Price to Cash Flow | 1.87745e+012 |
| Dividend | 6.43e+006 |
| Forward Dividend | 6.45e+006 |
| Dividend Yield | 43741500% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|